Human blood–brain barrier spheroid models for the evaluation of drugs targeting brain vascular inflammation
Journal of Pharmacological Sciences · 2026-09 · 162 (1) · 40-49
DOI: 10.1016/j.jphs.2026.06.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacological Sciences, 2026-09. Verfasst von Ayuka Ebisawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Advanced Drug Development Sciences, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, 192-0392, Japan. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Natalizumab, Spheroids, Cellular. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, Japan Society for the Promotion of Science, Promotion and Mutual Aid Corporation for Private Schools of Japan.
Abstract (Originalsprache)
The blood-brain barrier (BBB), primarily formed by brain microvascular endothelial cells (BMECs), restricts substance entry into the brain. BBB inflammation, involving barrier dysfunction and immune cell recruitment, contributes to neurological diseases and represents a therapeutic target. In this study, we characterized human immortalized cell-based multicellular spheroidal BBB (hiMCS-BBB) models as a tool for evaluating effects of BBB inflammation-targeted drugs. First, we examined the responses of the hiMCS-BBB models to the pro-inflammatory cytokine (TNF-α and IFN-γ) exposure. The cytokine treatment reduced claudin-5 protein expression levels at the BBB, accompanied by a 1.4 ± 0.1-fold increase in lucifer yellow permeability. Consistently, E-selectin protein expression was upregulated, accompanied by a 22.1-fold increase in THP-1 cell adhesion to the BBB. Then, we tested whether natalizumab (a monoclonal antibody used for multiple sclerosis treatment) and JPH203 (an inhibitor of L-type amino acid transporter 1) could modulate the immune cell adhesion. Both agents remarkably suppressed the cytokine-induced THP-1 cell adhesion to 0.2-fold relative to the respective controls. To summarize, our results demonstrate that the hiMCS-BBB models exhibit key features of BBB inflammation in response to inflammation stimuli and recapitulate clinically relevant responses to anti-inflammatory drugs, highlighting their potential to accelerate BBB-targeting drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Advanced Drug Development Sciences, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, 192-0392, Japan.
- Division of Anatomy and Neurobiology, Medical University of Gdansk, Gdansk, Poland.
- Laboratory of Advanced Drug Development Sciences, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, 192-0392, Japan. Electronic address: tomomif@toyaku.ac.jp.
Förderung
- Japan Science and Technology Agency
- Japan Society for the Promotion of Science
- Promotion and Mutual Aid Corporation for Private Schools of Japan
Zitieren
APA
Ebisawa, A., Morio, H., Minasato, A., Watanabe, H., Kunitomo, F., Rutkowska, A., & Furihata, T. (2026). Human blood–brain barrier spheroid models for the evaluation of drugs targeting brain vascular inflammation. Journal of Pharmacological Sciences, 162(1), 40-49. https://doi.org/10.1016/j.jphs.2026.06.005
Vancouver
Ebisawa A, Morio H, Minasato A, Watanabe H, Kunitomo F, Rutkowska A, et al. Human blood–brain barrier spheroid models for the evaluation of drugs targeting brain vascular inflammation. Journal of Pharmacological Sciences. 2026;162(1):40-49. doi:10.1016/j.jphs.2026.06.005
BibTeX
@article{Ebisawa2026,
author = {Ebisawa, Ayuka and Morio, Hanae and Minasato, Asuka and Watanabe, Hiromu and Kunitomo, Furano and Rutkowska, Aleksandra and Furihata, Tomomi},
title = {Human blood–brain barrier spheroid models for the evaluation of drugs targeting brain vascular inflammation},
journal = {Journal of Pharmacological Sciences},
year = {2026},
volume = {162},
number = {1},
pages = {40--49},
doi = {10.1016/j.jphs.2026.06.005}
}
EUVIMED